



#12

PATENT  
Docket No. 2026-4116US2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Bukh, et al  
Serial No. : 09/084,691 Group Art Unit: 1648  
Filed : May 26, 1998 Examiner: Zeman, M.  
For : NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF  
THE ENVELOPE 1 AND CORE GENES OF ISOLATES OF  
HEPATITIS C VIRUS AND THE USE OF REAGENTS DERIVED  
FROM THESE SEQUENCES IN DIAGNOSTIC METHODS AND  
VACCINES

Commissioner for Patents  
Washington, D.C. 20231

**STATEMENT UNDER 37 C.F.R. §1.821(f) OR §1.825(b)**

Sir:

I hereby certify that:

- [ ] The paper Sequence Listing and computer readable form of the  
Sequence Listing submitted herewith are identical (37 C.F.R.  
§1.821(f)).
- [X] The substitute paper Sequence Listing and substitute computer  
readable form of the Sequence Listing submitted herewith are  
identical. No new matter is included. (37 C.F.R. §1.825(b)).

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Date: June 7, 2001

By: William S. Feiler

William S. Feiler  
Registration No. 35,353

**CORRESPONDENCE ADDRESS:**  
MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154-0053  
(212) 758-4800 (Telephone)  
(212) 751-6849 (Facsimile)



Docket No. 2026-4116US2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Bukh, et al  
Serial No. : 09/084,691 Group Art Unit: 1648  
Filed : May 26, 1998 Examiner: Zeman, M.  
For : NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF  
THE ENVELOPE 1 AND CORE GENES OF ISOLATES OF  
HEPATITIS C VIRUS AND THE USE OF REAGENTS DERIVED  
FROM THESE SEQUENCES IN DIAGNOSTIC METHODS AND  
VACCINES

Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES**

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed February 2, 2001, applicant respectfully submits herewith a substitute paper sequence listing; Statement Under 37 CFR 1.825(b); and a substitute computer readable form of the Sequence Listing in replacement of the sequence listing now on file. No new matter is included.

The consensus sequences disclosed in Fig. 7A-K are now accompanied by SEQ ID No's and included among the sequences on the listing.

A three month Petition for Extension of Time with the appropriate fee is being filed simultaneously with this Response. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper or credit any overpayment to Deposit Account No. 13-4500. Order No. 2026-4116US2. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Date: June 7, 2001

By:

William S. Feiler

Registration No. 35,353

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P.

345 Park Avenue

New York, New York 10154-0053

(212) 758-4800 (Telephone)

(212) 751-6849 (Facsimile)